Arca
Skip to content

Immune thrombocytopenia (itp)

Drug research and approvals for immune thrombocytopenia (itp): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 90 studies of immune thrombocytopenia (itp) are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, FDA has 8 approved and 14 open orphan designations naming it, and the EU has 6 authorised medicines for it.

  • Recruiting worldwide: 90
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 8
  • EU medicines: 6

Recruiting Now

Newest start dates first, of 90 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Nov 5, 2021An interventional phase 2, open-label, one-arm, multicenter study to evaluate safety and efficacy of pf-06835375 in adult participants with moderate to severe…PF-06835375PfizerClosed
Dec 1, 2020A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study with an open-label extension to evaluate the efficacy and safety of…RILZABRUTINIB (PRN1008)PRINCIPIA BIOPHARMA INCOngoing
Apr 28, 2020A phase 3 multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of rozanolixizumab in adult study…ROZANOLIXIZUMAB (UCB7665)UCBClosed
Feb 21, 2019An adaptive, open-label, dose-finding, phase 1/2 study investigating the safety, pharmacokinetics, and clinical activity of rilzabrutinib (prn1008), an oral…RILZABRUTINIB (PRN1008)PRINCIPIA BIOPHARMA INCClosed
Nov 4, 2014A single arm, open-label, long-term efficacy and safety study of romiplostim in thrombocytopenic pediatric subjects with immune thrombocytopenia (itp)NPLATE (ROMIPLOSTIM)AmgenOngoing
Oct 10, 2014Open label, adaptive design, ascending, multiple-dose study to evaluate safety and efficacy of bms-986004 (anti-cd40l dab) in adult subjects with primary…BMS 986004 (ANTI-CD40L DOMAIN ANTIBODY)Bristol-Myers SquibbOngoing
Sep 18, 2013A rollover study to provide continued treatment with eltrombopagREVOLADEGSKPending

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 22
Aug 29, 2025Wayrilztreatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous…Genzyme Corporation (A Sanofi Company)Approved
Jul 24, 2025Doptelettreatment of thrombocytopenia in pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an…Sobi, Inc.Approved
Oct 17, 2019NplateNplate is indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient…Amgen, Inc.Approved
Jun 26, 2019avatrombopag maleateDOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an…Sobi, Inc.Approved
Dec 14, 2018NplateNplate is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who…Amgen, Inc.Approved
Apr 17, 2018fostamatinib disodium hexahydrateTAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an…Rigel Pharmaceuticals, Inc.Approved
Mar 8, 2013GammaplexIdiopathic thrombocytopenic purpuraBio Products LaboratoryApproved
Aug 22, 2008NplateTreatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient…Amgen, Inc.Approved
Oct 24, 2026sovleplenib acetatetreatment of primary immune thrombocytopeniaHUTCHMED LimitedDesignated
Aug 22, 2026pirtobrutinibtreatment of primary immune thrombocytopeniaEli Lilly and CompanyDesignated
Dec 4, 2025bispecific humanized IgG4 BCMA-directed CD3 T cell engager…treatment of immune thrombocytopenia (ITP)Lakefront Biotherapeutics West LLCDesignated
Feb 13, 2025Ianalumabtreatment of primary immune thrombocytopeniaNovartis Pharmaceutical CorporationDesignated
Dec 16, 2024rituximabtreatment of immune thrombocytopeniaODDIFACT SASDesignated
Jul 31, 2024recombinant human thrombopoietin (rhTPO)treatment of primary immune thrombocytopenia (ITP)3SBIO Inc. (Shenyang Sunshine Pharmaceuticals CO., Ltd.)Designated
Mar 20, 2024CevidoplenibTreatment of primary immune thrombocytopenia (ITP)Oscotec Inc.Designated

Medicines Authorised in the EU

Newest first
Dec 22, 2025Wayrilzrilzabrutinib · orphanSanofi B.V.EMA ↗
Mar 28, 2025Eltrombopag Accordeltrombopag · genericAccord Healthcare S.L.U.EMA ↗
Dec 12, 2024Eltrombopag Viatriseltrombopag · genericViatris LimitedEMA ↗
Jan 9, 2020TavlessefostamatinibInstituto Grifols S.A.EMA ↗
Mar 11, 2010RevoladeeltrombopagNovartis Europharm LimitedEMA ↗
Feb 4, 2009NplateromiplostimAmgen Europe B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.